Savara (SVRA) Invested Capital (2010 - 2026)
Savara (SVRA) reported Invested Capital of $176.0 million for Q1 2026, up 19.07% year-over-year from $147.8 million in Q1 2025, and down 13.34% on a QoQ basis from $203.1 million in Q4 2025.
Savara (SVRA) has 17 years of Invested Capital data on file, last reported at $176.0 million in Q1 2026.
- Quarterly Invested Capital rose 19.07% year-over-year to $176.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $176.0 million (up 19.07% YoY) and the FY2025 annual result came in at $203.1 million, up 18.48% from the prior year.
- Invested Capital retreated to $176.0 million in Q1 2026 per SVRA's latest filing, from $203.1 million in the prior quarter.
- Across five years, Invested Capital topped out at $203.1 million in Q4 2025 and bottomed at -$605000.0 in Q4 2022.
- The 5-year median for Invested Capital is $121.9 million (2024), against an average of $115.6 million.
- The widest annual swing landed in 2022, when Invested Capital sank 100.4%; it then jumped 63365.31% in 2024.
- Tracing SVRA's Invested Capital over 5 years: stood at -$605000.0 in 2022, then surged by 55.21% to -$271000.0 in 2023, then jumped by 63365.31% to $171.4 million in 2024, then climbed by 18.48% to $203.1 million in 2025, then fell by 13.34% to $176.0 million in 2026.
- Per Business Quant, the three latest SVRA Invested Capital figures stand at $176.0 million (Q1 2026), $203.1 million (Q4 2025), and -$155000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 595,226.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.96 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 14.38 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 19.36 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 31.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.08 Bn |
| 10 | Savara | 1.30 Bn | 1.30 Bn | - | 176.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 176.04 Mn |
| Dec 31, 2025 | 203.13 Mn |
| Sep 30, 2025 | -155,000.00 |
| Jun 30, 2025 | 120.48 Mn |
| Mar 31, 2025 | 147.85 Mn |
| Dec 31, 2024 | 171.45 Mn |
| Sep 30, 2024 | 199.35 Mn |
| Jun 30, 2024 | 101.73 Mn |
| Mar 31, 2024 | 121.86 Mn |
| Dec 31, 2023 | -271,000.00 |
| Sep 30, 2023 | 146.54 Mn |
| Jun 30, 2023 | 87.72 Mn |
| Mar 31, 2023 | 98.26 Mn |
| Dec 31, 2022 | -605,000.00 |
| Sep 30, 2022 | 116.51 Mn |
| Jun 30, 2022 | 127.04 Mn |
| Mar 31, 2022 | 148.98 Mn |
| Dec 31, 2021 | 152.83 Mn |
| Sep 30, 2021 | 159.40 Mn |
| Jun 30, 2021 | 165.38 Mn |
| Mar 31, 2021 | 175.12 Mn |
| Dec 31, 2020 | 64.38 Mn |
| Sep 30, 2020 | 76.63 Mn |
| Jun 30, 2020 | 83.80 Mn |
| Mar 31, 2020 | 87.32 Mn |
| Dec 31, 2019 | 103.70 Mn |
| Sep 30, 2019 | 106.80 Mn |
| Jun 30, 2019 | 112.80 Mn |
| Mar 31, 2019 | 101.80 Mn |
| Dec 31, 2018 | 108.22 Mn |
| Sep 30, 2018 | 121.60 Mn |
| Jun 30, 2018 | 84.58 Mn |
| Mar 31, 2018 | 93.70 Mn |
| Dec 31, 2017 | 119.31 Mn |
| Sep 30, 2017 | 74.65 Mn |
| Jun 30, 2017 | 79.77 Mn |
| Mar 31, 2017 | 5.93 Mn |
| Dec 31, 2016 | -34.33 Mn |
| Sep 30, 2016 | 24.78 Mn |
| Jun 30, 2016 | 28.94 Mn |
| Mar 31, 2016 | 32.13 Mn |
| Dec 31, 2015 | -16.34 Mn |
| Sep 30, 2015 | 35.08 Mn |
| Jun 30, 2015 | 42.54 Mn |
| Mar 31, 2015 | 50.11 Mn |
| Dec 31, 2014 | -18.30 Mn |
| Sep 30, 2014 | 45.25 Mn |
| Jun 30, 2014 | 50.22 Mn |
| Mar 31, 2014 | 52.79 Mn |
| Dec 31, 2013 | 47.81 Mn |
| Sep 30, 2013 | 53.06 Mn |
| Jun 30, 2013 | 57.90 Mn |
| Mar 31, 2013 | 36.55 Mn |
| Dec 31, 2012 | 41.79 Mn |
| Sep 30, 2012 | 46.29 Mn |
| Jun 30, 2012 | 49.08 Mn |
| Mar 31, 2012 | 52.96 Mn |
| Dec 31, 2011 | 56.78 Mn |
| Sep 30, 2011 | 43.15 Mn |
| Jun 30, 2011 | 46.40 Mn |
| Dec 31, 2010 | 26.69 Mn |